11 completed, 2 recruiting, 2 unknown, 1 not yet recruiting. 8 Phase 1, 6 Phase 3, 4 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Recruiting 2, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 6 | Completed 5, Unknown 1 |
| Phase 2 | 4 | Unknown 2, Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Vaxine Pty Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Therapeutic hepatitis B vaccine, Commercial Hepatitis B vaccine - Chronic Hepatitis b | Phase 1 / Phase 2 | Not yet recruiting | Vaxine Pty Ltd | 40 | 2026-03-01 | 2025-09-22 |
| Covid-19 and Influenza Oral Vaccine Study Covid-19 vaccine, Influenza vaccine - covid19 Infection, Influenza, Human | Phase 1 | Recruiting | Vaxine Pty Ltd | 100 | 2024-05-01 | 2025-09-17 |
| Autologous Tumour Vaccine Trial Radvax - Solid Tumor | Phase 1 | Recruiting | Vaxine Pty Ltd | 30 | 2023-02-10 | 2025-09-17 |
| Booster Study of SpikoGen COVID-19 Vaccine SpikoGen vaccine - COVID-19 | Phase 3 | Completed | Vaxine Pty Ltd | 81 | 2022-09-07 | 2025-09-17 |
| A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen) Advax-CpG55.2 adjuvanted recombinant spike protein - COVID-19 | Phase 3 | Completed | Vaxine Pty Ltd | 39 | 2022-08-15 | 2025-09-17 |
| Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine Spikogen/Covax-19 - COVID-19 | Phase 2 / Phase 3 | Unknown | Vaxine Pty Ltd | 200 | 2022-03-01 | 2024-08-07 |
| Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant - COVID-19 | Phase 3 | Completed | Cinnagen | 581 | 2022-02-23 | 2022-10-17 |
| Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant - COVID-19 | Not applicable | Completed | Cinnagen | 43 | 2022-02-04 | 2023-08-31 |
| Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, Saline placebo - COVID-19 | Phase 3 | Completed | Cinnagen | 300 | 2021-12-15 | 2022-10-14 |
| Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, Saline placebo - Covid19 | Phase 3 | Completed | Cinnagen | 16876 | 2021-08-07 | 2022-10-13 |
| Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, Saline placebo - Covid19 | Phase 2 | Completed | Cinnagen | 400 | 2021-05-30 | 2022-10-13 |
| Monovalent Recombinant COVID19 Vaccine COVID19 vaccine, Saline - Coronavirus Infection, COVID | Phase 1 | Completed | Vaxine Pty Ltd | 40 | 2020-06-30 | 2022-03-02 |
| Recombinant H7 Hemagglutinin Influenza Vaccine Trial Recombinant influenza hemagglutinin - Influenza, Avian | Phase 1 | Completed | Vaxine Pty Ltd | 150 | 2017-01-01 | 2019-05-07 |
| Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax) Delta-inulin, Dose finding comparison - Ant Sting, Immunotherapy | Phase 1 / Phase 2 | Unknown | Central Adelaide Local Health Network Incorporated | 40 | 2016-10-01 | 2020-08-11 |
| A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults recombinant influenza hemagglutinin, Advax1, Advax2 - Influenza | Phase 1 | Completed | Vaxine Pty Ltd | 270 | 2015-07-01 | 2019-05-07 |
| Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine HBsAg, PreS HBsAg, Advax-1(TM) - Exposure to Hepatitis B Virus | Phase 1 | Completed | Vaxine Pty Ltd | 240 | 2013-07-01 | 2019-05-07 |
COVID-19 (10) · Coronavirus Infections (3) · Influenza, Human (2) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Influenza in Birds (1) · Neoplasms (1)
SARS-CoV-2 recombinant spike protein with delta inulin and CpG-ODN adjuvant vaccine (9) · COVID-19 Vaccines (2) · Saline Solution (2) · Aluminum Hydroxide (1) · Engerix-B (1) · FANG vaccine (1) · Hepatitis B Surface Antigens (1) · Influenza Vaccines (1) · Sodium Chloride (1) · aluminum sulfate (1) · delta inulin (1)
Australia (11) · Iran (5)
Payam Tabarsi, M.D. (4) · Dimitar Sajkov, MBBS/PhD (2) · Dimitar Sajkov, MD, PhD (2) · David Gordon, MBBS, Ph.D (1) · Dimitar Sajkov, FRACP, PhD (1) · Dimitar Sajkov, MBBS (1) · Dimitar Sajkov, MD/PhD (1) · Jeffrey Barbara, MBBS PhD (1) · Mohsen Nafar, M.D. (1) · Nikolai Petrovsky, MBBS/PhD (1) · Nikolai Petrovsky, MD/PhD (1) · Pravin Hissaria, FRACP FRCPA (1)
PMID 39914274, PMID 35436611, PMID 35758850, PMID 36096430, PMID 41748259